Full Press Release Details
Zai Lab Announces Third Quarter 2022
Financial Results and Corporate Updates
-Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q continued revenue growth led by ZEJULA
-Regional strategic collaboration for TIVDAK (tisotumab vedotin) strengthens Zai Lab's leadership in developing and providing access to medicine to treat women's cancer in China
-Strong balance sheet with a cash position of $1.12 billion
-Company to host a conference call and webcast on November 10, 2022, at 8 00 a.m. ET
SHANGHAI and CAMBRIDGE, Mass., November 9, 2022 -- Zai Lab Limited (NASDAQ ZLAB HKEX 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the third quarter of 2022, along with recent product highlights and corporate updates.
"Zai Lab's third quarter was marked by a new regional and highly synergistic collaboration, strong revenue growth across our commercial products, and significant progress toward achieving our remaining 2022 corporate priorities," said Dr. Samantha Du, Founder, Chairperson and CEO, of Zai Lab. "The company's strategic positioning with respect to its targeted disease areas provides a robust and synergistic platform to benefit patients in Greater China and around the world as we continue to increase our sales and developmental efforts. Looking ahead, we expect this momentum to be bolstered by our late-stage development candidates that are progressing through pivotal studies and regulatory submissions. As one example, we reached an agreement with the NMPA on the development plan for a bridging study for KarXT in schizophrenia in China. In addition, our recently announced strategic collaboration with Seagen for the license of TIVDAK strengthens our ability to address unmet medical needs in women's cancer. TIVDAK is the first and only ADC approved in the U.S. for the treatment of adult patients with recurrent or metastatic cervical cancer. Zai Lab is progressing this asset in pivotal studies in China."
Recent Product Developments and Anticipated Milestones
ZEJULA is an oral, once-daily small-molecule poly (ADP-ribose) polymerase (PARP) 1 2 inhibitor. It is the only PARP inhibitor approved in the United States, the European Union, and China as a first-line maintenance monotherapy for patients with advanced ovarian cancer, regardless of their biomarker status.
Recent Product Highlights
Throughout this year, the U.S. Food and Drug Administration (FDA) has been reviewing data on PARP inhibitors, and other companies have issued Dear HCP Letters in the U.S. as a result of ongoing discussions with the FDA. In September 2022, Zai Lab partner GlaxoSmithKline (GSK) disclosed that it was in discussions with the FDA to discuss overall survival (OS) data from GSK's ENGOT-OV16 NOVA phase III clinical trial for adult patients with recurrent ovarian cancer irrespective of the gBRCA mutation. Zai Lab does not expect the FDA's discussions with GSK to impact its approval from the NMPA for ZEJULA in China. The NMPA's full approval of ZEJULA in the recurrent ovarian cancer setting is based on a separate study, the NORA study, which is a Phase 3 randomized, double-blind, placebo-controlled study of ZEJULA that the Company independently conducted in China. While the NORA study is not fully mature, to date, favorable trends have been observed in OS irrespective of gBRCA mutation status. We expect to present this data at a future scientific congress. As a result, the Company does not anticipate that its second-line all-comer label in China will be affected by the FDA's discussions with GSK. The Company also does not expect a change in its first-line label for ZEJULA the FDA's discussions with GSK do not apply to this indication.
Tumor Treating Fields
Tumor Treating Fields (TTFields) are electric fields that disrupt cancer cell division. Optune and Optune Lua, commercial TTFields devices, are approved or marketed in certain countries or regions for the treatment of newly diagnosed and recurrent glioblastoma and malignant pleural mesothelioma.
Recent Product Highlight
As of September 30, 2022, Optune has been listed in 72 regional customized commercial health insurance plans guided by provincial or municipal governments (or supplemental insurance plans) since its commercial launch in China in the third quarter of 2020, compared to 25 supplemental insurance plans as of September 30, 2021.
Anticipated 2022 Early 2023 Partner and Zai Milestones
Last patient enrollment anticipated in the Phase 3 pivotal METIS study evaluating the efficacy and safety of stereotactic radiosurgery plus TTFields compared to stereotactic radiosurgery alone in patients with brain metastases resulting from Non-small Cell Lung Cancer (NSCLC).
Top-line results from the Phase 3 pivotal LUNAR study in NSCLC in the early first quarter of 2023. Zai Lab joined the global LUNAR study in April 2021.
QINLOCK (Ripretinib)
QINLOCK is a switch-control tyrosine kinase inhibitor engineered to broadly inhibit KIT- and PDGFR -mutated kinases. It is the only therapeutic approved in the United States and China for advanced gastrointestinal stromal tumor (GIST) patients who have received prior treatment with three or more kinase inhibitors in the all-comer setting.
Recent Product Highlights
As of September 30, 2022, QINLOCK has been listed in 96 supplemental insurance plans since its commercial launch in China in May 2021, compared to 28 supplemental insurance plans as of September 30, 2021.
In August 2022, the recommendation level of QINLOCK for second-line treatments for advanced GIST patients was advanced from Level III to Level II (1A evidence) in the Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of GIST 2022.
Anticipated 2022 Zai Milestone
Seek National Reimbursement Drug List (NRDL) inclusion for a fourth-line GIST indication.
Adagrasib is a highly selective and potent oral small-molecule inhibitor of KRASG12C for treating KRASG12C-mutated NSCLC, colorectal cancer (CRC), pancreatic cancer, and other solid tumors.
Recent Product Highlights
In September 2022, Zai Lab partner Mirati Therapeutics, Inc. (Mirati) presented results from KRYSTAL-1, a multicohort Phase 1 2 study evaluating adagrasib with or without cetuximab in patients with advanced CRC harboring a KRASG12C mutation at the European Society for Medical Oncology (ESMO) Congress 2022.
-Of the evaluable patients in the adagrasib monotherapy cohort (n 43), the investigator assessed confirmed objective response rate (ORR) was 19% (8 43) and the disease control rate (DCR) was 86% (37 43). The median duration of response (DOR) was 4.3 months (95% CI, 2.3-8.3) and median PFS was 5.6 months (95% CI, 4.1-8.3).
-Of the evaluable patients in the adagrasib plus cetuximab combination cohort (n 28), the investigator assessed confirmed ORR was 46% (13 28) and the DCR was 100% (28 28). The median DOR was 7.6 months (95% CI 5.7-NE) and median PFS was 6.9 months (95% CI, 5.4-8.1).
-The prognosis for patients with CRC has historically been poor in later lines of therapy with response rates of approximately 1-2% and median PFS of approximately 2 months in patients with late-line CRC patients with KRASG12C-mutated CRC tend to have even worse outcomes than the broader CRC patient population.
-In the overall subset of patients with KRASG12C-mutated CRC evaluated in this study, adagrasib was found to be well-tolerated as a monotherapy and in combination with cetuximab. The majority of observed treatment-related adverse events (TRAEs) were grade 1-2 (59%) no grade 5 TRAEs were observed.
In August 2022, Zai Lab treated the first patient in Greater China for the global Phase 2 KRYSTAL-7 study of adagrasib in combination with pembrolizumab in first-line KRASG12C-mutated NSCLC patients.
Anticipated 2022 Partner Milestones
Potential FDA approval and commercial launch in the United States for adagrasib as the treatment for patients with NSCLC harboring the KRASG12C mutation who have received at least one prior systemic therapy Prescription Drug User Free Act (PDUFA) target action date of December 14, 2022.
Update for the Phase 2 KRYSTAL-7 study of adagrasib in combination with pembrolizumab in first-line KRASG12C-mutated NSCLC in the fourth quarter of 2022.
Additional clarity on the regulatory pathway of adagrasib monotherapy in first-line KRASG12C-mutated NSCLC.
Bemarituzumab is a potential first-in-class antibody that is being developed in gastric and gastroesophageal junction (GEJ) cancer as a targeted therapy for tumors that overexpress FGFR2b.
Recent Product Highlight
Zai Lab partner Amgen continues to enroll patients in several studies of bemarituzumab, including
-FORTITUDE-101, a Phase 3 study of bemarituzumab plus chemotherapy, versus placebo plus chemotherapy in first-line gastric cancer with FGFR2b overexpression.
-FORTITUDE-102, the Phase 3 portion of the 1b 3 study of bemarituzumab plus chemotherapy and nivolumab versus chemotherapy and nivolumab in first-line gastric cancer with FGFR2b overexpression.
Anticipated 2022 Early 2023 Zai Milestone
Initiate a registrational study of bemarituzumab in first-line advanced gastric and GEJ cancer in Greater China.
Odronextamab is a bispecific antibody designed to trigger tumor killing by linking and activating a cytotoxic T-cell (binding to CD3) to a lymphoma cell (binding to CD20).
Anticipated 2022 Zai Milestone
Complete enrollment in China in a potentially pivotal Phase 2 study in B-Cell Non-Hodgkin Lymphoma (B-NHL).
Anticipated 2022 Partner Milestone
Report additional results from the potentially pivotal Phase 2 study in B-NHL.
Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) designed to effectively target ROS1 and TRK A B C, with the potential to treat TKI-na ve or TKI-pretreated patients.
Recent Product Highlights
In October 2022, Zai Lab partner Turning Point Therapeutics (a wholly owned subsidiary of Bristol Myers Squibb Company) provided a clinical data update from the global, registrational Phase 1 2 TRIDENT-1 study of repotrectinib at the 34th EORTC-NCI-AACR (ENA) Symposium 2022.
-Repotrectinib continued to demonstrate meaningful clinical activity in patients with ROS1+ advanced NSCLC, who were TKI-na ve or TKI-pretreated, including with ROS1 G2032R resistance mutation. Durable responses and intracranial efficacy were observed in both TKI-na ve and TKI-pretreated patients.
-Repotrectinib also continued to show clinical activity in patients with NTRK+ advanced solid tumors who were TKI-na ve or TKI-pretreated, and responses were seen across diverse tumor types.
-Safety is well characterized, manageable with known protocols, and signals potential compatibility with long-term use.
In October 2022, Zai Lab completed enrollment in China in all cohorts of the registrational Phase 1 2 TRIDENT-1 study.
Anticipated Early 2023 Zai Milestone
Discuss regulatory pathway with the National Medical Products Administration (NMPA) at a pre-NDA meeting.
CLN-081 is an orally available, irreversible epidermal growth factor receptor (EGFR) inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild type EGFR.
Anticipated 2022 Partner Milestone
Initiate a pivotal study following the completion of a pharmacokinetic (PK) food effect study.
BLU-945 is a selective and potent investigational inhibitor of the activating EGFR L858R mutation and on-target T790M and C797S resistance mutations, for the potential treatment of EGFR-driven NSCLC.
Recent Product Highlight
In November 2022, Zai Lab partner Blueprint Medicines presented an update on the Phase 1 2 SYMPHONY trial data supporting plans to develop BLU-945 in combination with osimertinib in first-line EGFR L858R mutation-positive NSCLC.
Autoimmune Disorders
VYVGART (Efgartigimod)
Efgartigimod is an antibody fragment designed to reduce disease-causing immunoglobulin G (IgG) autoantibodies and block the IgG recycling process. It binds to the neonatal Fc receptor (FcRn), which is widely expressed throughout the body and plays a central role in rescuing IgG from degradation.
Recent Product Highlights
As of November 1, 2022, VYVGART (efgartigimod alfa-fcab) has been listed in 10 supplemental insurance plans in China.
In September 2022, Zai Lab partner argenx announced the submission of a BLA to the FDA for subcutaneous (SC) efgartigimod for the treatment of generalized myasthenia gravis (gMG) in adult patients.
In September 2022, argenx also announced that the European Commission (EC) has granted marketing authorization for VYVGART as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody positive.
Anticipated 2022 Early 2023 Zai Milestones
Launch the proof-of-concept trials in two autoimmune renal diseases.
Continue to explore and advance additional indications in coordination with argenx.
Anticipated Early 2023 Partner Milestone
Report topline data from the registrational ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy (CIDP) in the first quarter of 2023.
NUZYRA (Omadacycline)
NUZYRA is a once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Zai Lab led the China development and obtained approval by the NMPA in December 2021.
Anticipated 2022 Zai Milestone
Seek NRDL inclusion for CABP and ABSSSI indications.
Sulbactam-Durlobactam (SUL-DUR, Asia Pacific Rights)
Sulbactam-Durlobactam is a beta-lactam beta-lactamase inhibitor combination that provides unique activity against Acinetobacter organisms, including carbapenem-resistant strains.
Anticipated 2022 Early 2023 Zai Milestone
Submit an NDA to the NMPA.
KarXT combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist. In November 2021, Zai partnered with Karuna Therapeutics, Inc. (Karuna) to develop KarXT in Greater China for the treatment of schizophrenia and possibly other indications like dementia-related psychosis.
Recent Product Highlights
In September, 2022, Zai Lab obtained agreement from the NMPA on the development plan of a bridging study in schizophrenia in China.
In October 2022, Zai Lab partner Karuna announced that data from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia was shared at the 35th European College of Neuropsychopharmacology (ECNP) Congress in Vienna, Austria. A poster presentation and symposium included previously reported efficacy and safety data, as well as new additional safety data from the trial.
Karuna initiated the Phase 3 ADEPT-1 study evaluating KarXT as a treatment for psychosis in Alzheimer's disease in the third quarter of 2022.
Karuna completed enrollment in the Phase 3 EMERGENT-3 trial in schizophrenia in the fourth quarter of 2022.
Anticipated Early 2023 Partner Milestone
Report topline data from the Phase 3 EMERGENT-3 trial in schizophrenia in the first quarter of 2023.
Global R D Autoimmune Disorder Programs
ZL-1102 (IL-17 Human VH Antibody Fragment, Global Rights)
ZL-1102 is a novel human VH antibody fragment (Humabody ) targeting the IL-17A cytokine with high affinity and avidity. Unlike other anti-IL-17 products, ZL-1102 is being developed as a topical treatment for mild-to-moderate chronic plaque psoriasis (CPP).
Recent Product Highlight
In September 2022, Zai Lab presented results of the Phase 1 proof-of-concept study for ZL-1102 at the 2022 European Academy of Dermatology and Venereology Congress (EADV) in Milan, Italy.
Anticipated 2022 Early 2023 Zai Milestone
Initiate a global Phase 2 study for CPP.